Literature DB >> 15602200

Antibodies to type III group B streptococcal polysaccharide in breast milk.

Morven S Edwards1, Flor M Munoz, Carol J Baker.   

Abstract

We compared concentrations of type III group B streptococcal capsular polysaccharide (CPS)-specific IgG and IgA in archived 2-month-postpartum breast milk from 9 women with > or =1 microg/ml and 9 with < 1 microg/ml type III CPS-specific IgG in serum. Type III CPS-specific antibodies were not detectable consistently but were measurable in breast milk from some women in both groups, indicating their potential for a role in prevention or amelioration of late onset group B streptococcal disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15602200     DOI: 10.1097/01.inf.0000142333.72511.8c

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  4 in total

Review 1.  Increased Risk of Group B Streptococcus Invasive Infection in HIV-Exposed but Uninfected Infants: A Review of the Evidence and Possible Mechanisms.

Authors:  Nicolas Dauby; Mustapha Chamekh; Pierrette Melin; Amy L Slogrove; Tessa Goetghebuer
Journal:  Front Immunol       Date:  2016-11-16       Impact factor: 7.561

2.  Opsonophagocytic Antibodies to Serotype Ia, Ib, and III Group B Streptococcus among Korean Infants and in Intravenous Immunoglobulin Products.

Authors:  Han Wool Kim; Ji Hyen Lee; Hye Kyung Cho; Hyunju Lee; Ho Seong Seo; Soyoung Lee; Kyung Hyo Kim
Journal:  J Korean Med Sci       Date:  2017-05       Impact factor: 2.153

Review 3.  Breast milk and Group B streptococcal infection: vector of transmission or vehicle for protection?

Authors:  Kirsty Le Doare; Beate Kampmann
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

4.  SIgA, TGF-β1, IL-10, and TNFα in Colostrum Are Associated with Infant Group B Streptococcus Colonization.

Authors:  Kirsty Le Doare; Katie Bellis; Amadou Faal; Jessica Birt; Daniel Munblit; Holly Humphries; Stephen Taylor; Fiona Warburton; Paul T Heath; Beate Kampmann; Andrew Gorringe
Journal:  Front Immunol       Date:  2017-10-20       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.